202 related articles for article (PubMed ID: 17200962)
1. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.
Galsky MD; Iasonos A; Mironov S; Scattergood J; Boyle MG; Bajorin DF
Cancer; 2007 Feb; 109(3):549-55. PubMed ID: 17200962
[TBL] [Abstract][Full Text] [Related]
2. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.
Hussain M; Vaishampayan U; Du W; Redman B; Smith DC
J Clin Oncol; 2001 May; 19(9):2527-33. PubMed ID: 11331332
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Hainsworth JD; Meluch AA; Litchy S; Schnell FM; Bearden JD; Yost K; Greco FA
Cancer; 2005 Jun; 103(11):2298-303. PubMed ID: 15856431
[TBL] [Abstract][Full Text] [Related]
4. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Milowsky MI; Nanus DM; Maluf FC; Mironov S; Shi W; Iasonos A; Riches J; Regazzi A; Bajorin DF
J Clin Oncol; 2009 Sep; 27(25):4062-7. PubMed ID: 19636012
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.
Morales-Barrera R; Bellmunt J; Suárez C; Valverde C; Guix M; Serrano C; Gallén M; Carles J
Eur J Cancer; 2012 Aug; 48(12):1816-21. PubMed ID: 22595043
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Grivas PD; Hussain M; Hafez K; Daignault-Newton S; Wood D; Lee CT; Weizer A; Montie JE; Hollenbeck B; Montgomery JS; Alva A; Smith DC
Urology; 2013 Jul; 82(1):111-7. PubMed ID: 23706253
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
Kanai K; Kikuchi E; Ohigashi T; Miyajima A; Nakagawa K; Nakashima J; Oya M
Int J Clin Oncol; 2008 Dec; 13(6):510-4. PubMed ID: 19093178
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
Hainsworth JD; Burris HA; Erland JB; Morrissey LH; Meluch AA; Kalman LA; Hon JK; Scullin DC; Smith SW; Greco FA
Cancer; 1999 Mar; 85(6):1269-76. PubMed ID: 10189131
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
11. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.
Bamias A; Moulopoulos LA; Koutras A; Aravantinos G; Fountzilas G; Pectasides D; Kastritis E; Gika D; Skarlos D; Linardou H; Kalofonos HP; Dimopoulos MA
Cancer; 2006 Jan; 106(2):297-303. PubMed ID: 16342065
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
Matsumoto K; Irie A; Satoh T; Okazaki M; Iwamura M; Baba S
Int J Urol; 2007 Nov; 14(11):1000-4; discussion 1004. PubMed ID: 17956525
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
Hussain MH; MacVicar GR; Petrylak DP; Dunn RL; Vaishampayan U; Lara PN; Chatta GS; Nanus DM; Glode LM; Trump DL; Chen H; Smith DC;
J Clin Oncol; 2007 Jun; 25(16):2218-24. PubMed ID: 17538166
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.
Calabrò F; Lorusso V; Rosati G; Manzione L; Frassineti L; Sava T; Di Paula ED; Alonso S; Sternberg CN
Cancer; 2009 Jun; 115(12):2652-9. PubMed ID: 19396817
[TBL] [Abstract][Full Text] [Related]
16. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
17. Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
Ichioka D; Miyazaki J; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Nishiyama H
Jpn J Clin Oncol; 2015 Sep; 45(9):867-73. PubMed ID: 26056328
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.
Kaya AO; Coskun U; Ozkan M; Sevinc A; Yilmaz AU; Gumus M; Unal OU; Ozdemir NY; Alici S; Berk V; Degerli H; Oner MK; Ozturk C; Kefeli U; Camcı C;
Onkologie; 2012; 35(10):576-80. PubMed ID: 23038228
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
20. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbæk M; Nilsson C; Moe M; Carus A; Öfverholm E; Lahdenperä O; Brandberg Y; Johansson H; Hellström M; Maase HV; Pappot H; Ullén A
Eur J Cancer; 2020 Mar; 127():173-182. PubMed ID: 31648851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
